BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36170166)

  • 61. Major clinical research advances in gynecologic cancer in 2017.
    Suh DH; Kim M; Lee KH; Eom KY; Kjeldsen MK; Mirza MR; Kim JW
    J Gynecol Oncol; 2018 Mar; 29(2):e31. PubMed ID: 29468855
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gene Panel Testing in Hereditary Breast Cancer.
    Rostami P; Zendehdel K; Shirkoohi R; Ebrahimi E; Ataei M; Imanian H; Najmabadi H; Akbari MR; Sanati MH
    Arch Iran Med; 2020 Mar; 23(3):155-162. PubMed ID: 32126783
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Factors that impact risk management decisions among women with pathogenic variants in moderate penetrance genes associated with hereditary breast cancer.
    Napoli M; Lewis J; Hopper J; Widmeyer K
    J Genet Couns; 2020 Dec; 29(6):960-970. PubMed ID: 32012395
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.
    Elliott E; Speare V; Coggan J; Espenschied C; LaDuca H; Yussuf AF; Burgess K; Gray P; Cobleigh M; Rao R; Patel J; Kuzel T; Buckingham LE; Usha L
    Cancer Rep (Hoboken); 2020 Dec; 3(6):e1287. PubMed ID: 32881420
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
    Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Kirshner JJ; Krop IE; Levinson J; Modi S; Patt DA; Perlmutter J; Winer EP; Lin NU
    J Clin Oncol; 2018 Sep; 36(27):2804-2807. PubMed ID: 29939840
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
    Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
    PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
    Churpek JE; Marquez R; Neistadt B; Claussen K; Lee MK; Churpek MM; Huo D; Weiner H; Bannerjee M; Godley LA; Le Beau MM; Pritchard CC; Walsh T; King MC; Olopade OI; Larson RA
    Cancer; 2016 Jan; 122(2):304-11. PubMed ID: 26641009
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
    BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
    Quon H; Vapiwala N; Forastiere A; Kennedy EB; Adelstein DJ; Boykin H; Califano JA; Holsinger FC; Nussenbaum B; Rosenthal DI; Siu LL; Waldron JN
    J Clin Oncol; 2017 Dec; 35(36):4078-4090. PubMed ID: 29064744
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
    Garber HR; Litton JK
    Curr Opin Oncol; 2019 May; 31(3):247-255. PubMed ID: 30789866
    [TBL] [Abstract][Full Text] [Related]  

  • 74. New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
    Harvey-Jones E; Vinas Villaro G; Tutt A
    Cancer J; 2021 Nov-Dec 01; 27(6):441-456. PubMed ID: 34904807
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
    Pierce LJ; Strawderman M; Narod SA; Oliviotto I; Eisen A; Dawson L; Gaffney D; Solin LJ; Nixon A; Garber J; Berg C; Isaacs C; Heimann R; Olopade OI; Haffty B; Weber BL
    J Clin Oncol; 2000 Oct; 18(19):3360-9. PubMed ID: 11013276
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 77. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
    Fogelman DR; Wolff RA; Kopetz S; Javle M; Bradley C; Mok I; Cabanillas F; Abbruzzese JL
    Anticancer Res; 2011 Apr; 31(4):1417-20. PubMed ID: 21508395
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Systemic treatment of early breast cancer - current state of knowledge after the conference St Gallen 2017].
    Sarosiek T
    Pol Merkur Lekarski; 2017 Nov; 43(257):232-236. PubMed ID: 29231918
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.
    Jara L; Morales S; de Mayo T; Gonzalez-Hormazabal P; Carrasco V; Godoy R
    Biol Res; 2017 Oct; 50(1):35. PubMed ID: 28985766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.